In the PARADIGM-HF trial [12], neprilysin inhibition combined with inhibition of AT1 receptors was superior to ACE inhibition by enalapril in reducing both the risks of death and hospitalization for HF in patients with HF and reduced LVEF. The gene discussed is AGTR1; the disease is hydrops fetalis.